Dr. Calum MacRae is the Chief of Cardiovascular Medicine at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. He is also an Associate Member at the Broad Institute and a Principal Faculty Member at the Harvard Stem Cell Institute. A cardiologist, geneticist and developmental biologist, he has trained in Edinburgh, London and Boston. He came to Harvard Medical School for a fellowship in cardiovascular genetics in 1991. He continued his research training at Massachusetts General Hospital in 1996 with focus on developmental biology. He returned to Brigham and Women’s in 2009 and rose to chief of cardiovascular medicine in 2014.
His research interest is in understanding the fundamental mechanisms of disease using human studies and complementary efforts combining systems level modeling with empiric high-throughput biology in the zebrafish. His lab uses automated screens in fish to define the genetic architecture of disease and to explore gene-drug (or environment) interactions through the interrogation of large-scale chemical libraries. His clinical interests include genomic medicine, innovation in phenotyping and the redesign of clinical care. Under his leadership, the Brigham Cardiology team has successfully engaged in a number of innovative collaborations in cardiovascular care optimization with a wide range of industry partners.
In October 2016, Dr. MacRae became the recipient of One Brave Idea, a $75 million 5-year research award to study coronary heart disease and its consequences. This unique team based program is funded by the American Heart Association, Verily and Astra Zeneca. His proposal was chosen amongst a group of 349 applicants from 22 countries who sought the project to identify an entirely new approach to eradicate the number one killer of Americans. His visionary approach holds promise for addressing a broad set of diseases.